Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $34.24 million. The enterprise value is -$32.02 million.
Important Dates
The next estimated earnings date is Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 43.95 million shares outstanding. The number of shares has increased by 60.24% in one year.
| Shares Outstanding | 43.95M |
| Shares Change (YoY) | +60.24% |
| Shares Change (QoQ) | +57.46% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 25.19% |
| Float | 29.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.53 |
| Forward PS | n/a |
| PB Ratio | 1.02 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.02 |
| Quick Ratio | 1.94 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -166.76 |
Financial Efficiency
Return on equity (ROE) is -130.03% and return on invested capital (ROIC) is -65.98%.
| Return on Equity (ROE) | -130.03% |
| Return on Assets (ROA) | -45.75% |
| Return on Capital (ROIC) | -65.98% |
| Revenue Per Employee | $32,288 |
| Profits Per Employee | -$897,685 |
| Employee Count | 73 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.10% in the last 52 weeks. The beta is -0.06, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -69.10% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 40.73 |
| Average Volume (20 Days) | 208,879 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, XLO had revenue of $2.36 million and -$65.53 million in losses. Loss per share was -$1.49.
| Revenue | 2.36M |
| Gross Profit | 2.36M |
| Operating Income | -66.70M |
| Pretax Income | -65.53M |
| Net Income | -65.53M |
| EBITDA | -64.91M |
| EBIT | -66.70M |
| Loss Per Share | -$1.49 |
Full Income StatementBalance Sheet
The company has $74.95 million in cash and $8.69 million in debt, giving a net cash position of $66.26 million or $1.51 per share.
| Cash & Cash Equivalents | 74.95M |
| Total Debt | 8.69M |
| Net Cash | 66.26M |
| Net Cash Per Share | $1.51 |
| Equity (Book Value) | 33.42M |
| Book Value Per Share | 0.76 |
| Working Capital | 39.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.35 million and capital expenditures -$21,000, giving a free cash flow of -$17.37 million.
| Operating Cash Flow | -17.35M |
| Capital Expenditures | -21,000 |
| Free Cash Flow | -17.37M |
| FCF Per Share | -$0.40 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,830.04% |
| Pretax Margin | -2,780.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -736.78% |